Screening 1

• FC 11-01 • High-risk human papillomavirus screening roll-out in Norway See abstract > M. Mari NYGÅRD • FC 11-02 • Extended screening intervals: evidence from the artistic trial cohort See abstract > C. C. GILHAM • FC 11-03 • 4-year exit results for women with no CIN2 or worse detected in earlier screening rounds in the HPV focal trial See abstract > A. A. COLDMAN • FC 11-04 • Cancer cases identified in a randomized implementation of primary HPV-testing in the Norwegian cervical cancer screening programme See abstract > B. B. ENGESÆTER • FC 11-05 • Detection of CIN2+ in women with normal cytology using a 3-type HPV mRNA test See abstract > S. S. SORBYE • FC 11-06 • The clinical and economic impact of HPV extended genotyping for the individualized risk management of patients: results of an economic model See abstract > L. L.T. THOMSEN • FC 11-07 • HPV primary screening pilot study: molecular testing of potential triage strategies for HPV-positive women See abstract > C. C. WHITE • FC 11-08 • Genotyping and cytologic triage of HPV positive women for the detection of cervical high-grade lesions See abstract > M. M. EL-ZEIN • FC 11-09 • 5-type HPV mRNA negative women in triage of ASC-US/LSIL may return to screening at 3- year interval - an historical prospective cohort study See abstract > F. F.E. SKJEKDESTAD • FC 11-10 • Validation and implementation of a next-generation qPCR diagnostic tool for human papillomavirus type 67 screening See abstract > J. John Paul BOGERS • FC 11-11 • Presence of koilocytosis in low-grade cytology of hrHPV-positive women is a negative predictor for CIN3+ See abstract > A. A.G. SIEBERS • FC 11-12 • MEASURING CYTOLOGY REPRODUCIBILITY IN THE NEW DUTCH CERVICAL SCREENING PROGRAM See abstract > A. Anne Uyterlinde